Nepafenac and lubricant

ApprovedSmall molecule

IInstituto de Oftalmología Fundación Conde de Valenciana

Nepafenac and lubricant is one of 6 small molecule programs targeting Epiphora. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

EpiphoraActive, not recruiting

EpiphoraApproved

Active, not recruiting

Competition

Competitive Landscape

9 competitors in Epiphora

#DrugCompanyPhaseTrials

Neoral

Novartis

Approved

—2

Decadron

AAspen Global Incorporated

Marcaine

Botox

RRevance Therapeutics, Inc.

Phase 2

1 5

Botox

VVitae Pharmaceuticals Inc., an Allergan affiliate

Phase 2

—6

Nepafenac and lubricant

IInstituto de Oftalmología Fundación Conde de Valenciana

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Epiphora1 trial

A Comparative Analysis of the Effectiveness of Nepafenac Combined With a Lubricant Versus a Lubricant Alone in the Treatment of Epiphora Associated With Lacrimal Punctum Stenosis

Active, not recruiting·IInstituto de Oftalmología Fundación Conde de Valenciana·Phase 4·NCT07372014·68 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Nepafenac and lubricant. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Nepafenac and lubricant compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Nepafenac and lubricant. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Instituto de Oftalmología Fundación Conde de Valenciana company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: IInstituto de Oftalmología Fundación Conde de Valenciana

Nepafenac and lubricant

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Epiphora1 trial

References

Drug Info

Quick Facts

Related News